Cibus Inc (CBUS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.59+0.63%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Reduce annual net cash usage to $30M or less: FCF guidance not reported vs 30M target.
Cibus aims to cut annual cash use to $30 million or less in 2026. The new CEO Craig Wichner brings fresh leadership. Analysts expect revenue to double next year. The company has runway into early 2027 despite delays.
Cibus is still loss-making with negative EPS expected through 2027. The U.S. rice launch delay to 2029 hurts cash flow goals. Recent earnings misses and workforce cuts show ongoing struggles. The stock is volatile and risky.
The price is about 46% above our fair value near $1. Analysts expect 100% revenue growth. Our view is cautious given ongoing losses and cash burn risks.
Breaks if: annual net cash usage exceeds $30 million in FY26
Continue cost discipline and operational efficiency to reduce annual net cash usage to approximately $30 million or less in 2026.
Stated as a priority in 4 of last 4 quarters. Management targeted reducing annual net cash usage to approximately $30 million or less in 2026, with guidance shifting from $30 million to $35 million exiting 2026. Quarterly net cash usage declined 19% sequentially and 31% year over year in 2026-Q2, showing progress but with a slight upward revision in run-rate guidance. The trajectory is delivering with some recent cost discipline offset by strategic investments.
“Capital discipline and operational efficiency: Now expect an annual net cash usage run-rate of approximately $35 million exiting 2026.”
“On target to deliver annual net cash usage of approximately $30 million or less in 2026.”
“On target to achieve goal of reducing annual net cash usage to approximately $30 million or less during 2026.”
“The Company targets a reduced annual net cash usage of $30 million by 2026.”
Breaks if: CEO transition fails to improve execution or causes disruption
Breaks if: YoY revenue growth falls below 50% next year
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story in a high-risk sector. The current thesis state reflects a cautious outlook due to recent earnings misses and elevated risk of future misses.
The market appears to be pricing in a fragile situation, with a premium valuation compared to peers. However, the expectations gap suggests that investors are not fully accounting for the company's recent performance challenges.
Fundamentals are likely to remain under pressure, given the high probability of an earnings miss in the near term. Management is making progress on cash usage and commercialization efforts, but the mixed results indicate uncertainty.
The thesis hinges on management's ability to meet its cash usage targets and successfully commercialize new products. Additionally, the performance of sector bellwethers and overall economic conditions will significantly impact CBUS's trajectory.
Over the next 1 to 3 years, CBUS faces a complex mix of opportunities and risks that will require careful monitoring. Not investment advice.
The most important moves since the prior daily snapshot.
Signal changed from 'mixed' to 'cautious'.
Mixed, the news cuts both ways. The company missed revenue estimates in Q2 2026. This suggests slower growth due to delays in product launches. However, management outlined a potential $20-40 million annual revenue opportunity from biofragrances. The delay in the Latin America rice launch pushes revenue to 2028. This impacts growth expectations for the company.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.